Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/1/2002


1.		Phase I/II Study of Immunization with MAGE-3 or Melan-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 in Patients with Metastatic Melanoma (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Not specified				NCI				UCCRC-9018 UCCRC-8381, NCI-G97-1162, NCT00002952

Last Modified: 12/1/1999 First Published: 9/1/1999


2.		Phase I/II Study of Immunization With MAGE-3 Plus Immunological Adjuvant SB AS-2 in HLA Class I Patients With MAGE-3 Positive Refractory Malignant Tumors (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18								EORTC-18972-13971/LUD97-002

Last Modified: 5/7/2007 First Published: 6/23/2003


3.		Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-11447A NCI-1330, NCT00064168, 1330

Last Modified: 11/25/2008 First Published: 5/28/2004


4.		Phase II Pilot Study of a Multipeptide (gp100 Antigen, MAGE-3, and Tyrosinase Peptide) Melanoma Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Patients With Resected Stage IIC, III, or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				LAC-USC-10M033 LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189

Last Modified: 10/3/2006 First Published: 4/1/1999


5.		Phase I Study of Dendritic Cell Immunotherapy in Patients With Metastatic Melanoma (Summary Last Modified 09/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 80				NCI				BAYUMC-098004 NCI-T98-0054, NCT00003792, T98-0054

Select All on One Page